Introduction
============

Phenotypic variation provides the raw materials for evolution by natural selection. Genetic variation together with interaction with non-genetic factors is the underlying driving force of the phenotypic changes ([@b43-bbi-2008-015]). In the past several years, genetic studies of gene expression have treated transcript abundance itself as a quantitative trait and have mapped it to human genome polymorphisms such as expression quantitative trait loci (eQTLs) ([@b45-bbi-2008-015]). Unlike rare or Mendelian disease, common diseases such as diabetes, cancer, depression and heart disease as well as individual responses to drug treatments have been shown to be caused by different genes or their combination with environmental factors. Various studies suggest that common DNA sequence variants in genes, especially single nucleotide polymorphisms (SNPs) are responsible for many of these examples of variation in development of diseases, responses to pathogens, chemicals and drugs ([@b21-bbi-2008-015]; [@b9-bbi-2008-015]; [@b26-bbi-2008-015]; [@b44-bbi-2008-015]; [@b46-bbi-2008-015]). The goal of the International HapMap Project ([@b33-bbi-2008-015]) is to develop a haplotype map of the human genome, the HapMap, to describe the common patterns of human DNA sequence variation. The HapMap is expected to be a key resource for researchers to find genes affecting health, disease and response to drugs and environmental factors.

The exploration of quantitative variation in human populations has become one of the major priorities for medical genetics. The successful identification of variants that contribute to complex traits such as gene expression and drug response is highly dependent on reliable assays and genetic maps. In this review, we briefly introduce the publicly available HapMap resource followed by a discussion of the recent progress in two areas significantly benefited from the HapMap resource: gene expression variation studies and pharmacogenomic studies. This resource is providing new insights into the human genome and cellular make-up and its impact on our understanding of the molecular basis of variable response to drugs and regulation of gene expression. We also discuss the advantages and limitations of the HapMap resource.

Publicly Available HapMap Resource
==================================

Four populations were selected for inclusion in the International HapMap Project ([@b33-bbi-2008-015]; [@b34-bbi-2008-015]; [@b35-bbi-2008-015]; [@b25-bbi-2008-015]): 30 trios from Ibadan, Nigeria (YRI), 30 trios of U.S. residents of northern and western European ancestry (CEU), 45 unrelated individuals from Tokyo, Japan (JPT) and 45 unrelated Han Chinese individuals from Beijing, China (CHB) ([Fig. 1](#f1-bbi-2008-015){ref-type="fig"}). Epstein Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) were derived from these individuals. [Table 1](#t1-bbi-2008-015){ref-type="table"} lists the datasets that have been made public on these populations by the HapMap Project and other laboratories. They can be grouped in three major catogories: (1) genotypic data, (2) gene expression data and (3) other phenotypic data.

Genotypic data on the HapMap cell lines
---------------------------------------

The HapMap web site ([@b56-bbi-2008-015]) is the primary portal to genotypic data produced as part of the International HapMap Project ([Table 1](#t1-bbi-2008-015){ref-type="table"}). More than 4 million SNPs (with a minor allele frequency 35%) were genotyped in 270 LCLs from the four populations. Available data also include assay design information, allele frequency information, raw genotypes, and analytic results including pairwise linkage disequilibrium (LD) between SNPs and phased haplotypes. There are also public datasets for copy number variation (CNV), a structural genetic variation different from SNPs. The Database for Genomic Variants ([@b32-bbi-2008-015]; [@b47-bbi-2008-015]) contains the CNV data on 55 unrelated CEU samples using array-based comparative genomic hybridization ([@b4-bbi-2008-015]). More comprehensive CNV data on 270 HapMap cell lines have recently been made public by Stranger et al. ([@b54-bbi-2008-015]).

Gene expression data on the HapMap cell lines
---------------------------------------------

Gene expression data using different microarray platforms have been made public through Gene Expression Omnibus (GEO) for the four populations in the HapMap Project ([Table 1](#t1-bbi-2008-015){ref-type="table"}). Although a comprehensive comparison of these particular expression datasets has not been reported (a potential topic for researchers using these datasets), performance across microarray platforms (e.g. Affymetrix, Illumina, GE Healthcare and Agilent) has been shown to be generally reliable versus other quantitative gene expression technologies such as TaqMan assays ([@b13-bbi-2008-015]). One potential problem with the use of expression microarrays is that oligonucleotide hybridization could be affected by polymorphisms located within probes ([@b27-bbi-2008-015]). It has been shown that sequence polymorphisms can result in many false-positives when testing for *cis* eQTLs ([@b3-bbi-2008-015]). A recent version of expression dataset using the Affymetrix GeneChip^®^ Human Exon 1.0ST Array took an extra step to filter out probesets affected by SNPs maintained in dbSNP (a database of SNP data curated by the National Center for Biotechnology Information) when summarizing gene expression ([@b60-bbi-2008-015]).

Other phenotypic data
---------------------

Other phenotypic data such as cell growth inhibition and/or apoptosis after drug treatment and drug metabolizing enzyme activity are being generated by various laboratories that use the HapMap cell lines as experimental models ([@b19-bbi-2008-015]; [@b58-bbi-2008-015]; [@b28-bbi-2008-015]; [@b29-bbi-2008-015]; [@b30-bbi-2008-015]). Published pharmacology-related phenotypic data on the HapMap samples can be accesed at the PharmGKB ([@b39-bbi-2008-015]) web site ([Table 1](#t1-bbi-2008-015){ref-type="table"}).

Genetic Determinants of Gene Expression Variation
=================================================

Gene expression as a complex trait or phenotype is believed to be a composite reflection of multiple genetic and non-genetic factors and the genetic contribution is consequently often difficult to characterize ([@b53-bbi-2008-015]; [@b24-bbi-2008-015]; [@b59-bbi-2008-015]). Understanding patterns of expression variation within and among population groups will provide important insights into the molecular basis of phenotypic diversity and the interpretation of patterns of expression variation in disease. The International HapMap resource along with association studies has allowed researchers to begin to characterize the genetic contribution to gene expression variation observed between individuals and populations. Impressively, with the availability of millions of genotypes already determined for cell lines derived from major world populations, the HapMap resource has accelerated these gene expression studies.

An early study using 35 Centre d'Etude du Polymorphisme Humain (CEPH) LCLs including some HapMap samples examined \~2500 expressed genes for natural variation in gene expression and identified genes whose transcript levels differed greatly among unrelated individuals ([@b14-bbi-2008-015]; [@b15-bbi-2008-015]). They also found evidence for familial aggregation of expression phenotype by comparing variation among unrelated individuals, among siblings within families and between monozygotic twins. These observations suggest that there is a genetic contribution to polymorphic variation in the level of gene expression. In contrast, using 60 unrelated CEU samples from the HapMap, Stranger et al. scanned 630 genes (374 expressed) for association of SNPs with inter-individual expression variation in LCLs. The signal proximal (*cis*-) to the genes of interest was found to be more abundant and more stable than those distal and (*trans-*) across statistical methodologies ([@b53-bbi-2008-015]). Impressively, by regional association with only the HapMap SNP markers that had strong linkage evidence from a previous study ([@b42-bbi-2008-015]), Cheung et al. were able to confirm the linkage results and narrow the candidate regulatory regions for many expression phenotypes of the 374 phenotypes they surveyed, while a genome-wide association using \>770,000 HapMap SNPs yielded highly significant results that point to the same locations as the genome scans for about 50% of the expression phenotypes. ([@b16-bbi-2008-015]). Recently, Bergen et al. investigated the role of *cis* sequence effects in a group of genes commonly studied in cancer research in human LCLs. Based on their results and the extensive literature, one in four genes exhibits significant *cis* sequence effects, and for these genes, about 30% of gene expression variation is accounted for by *cis* sequence variation ([@b8-bbi-2008-015]).

Populations differ in prevalence of many complex genetic diseases, such as diabetes and cardiovascular disease. However, the genetic basis for population differences in clinical outcomes and risk of disease is not fully understood ([@b22-bbi-2008-015]; [@b11-bbi-2008-015]; [@b36-bbi-2008-015]; [@b10-bbi-2008-015]; [@b12-bbi-2008-015]; [@b28-bbi-2008-015]). Although contributors to the differences are likely to include socioeconomic and/or environmental factors, genetic variation, including variation affecting gene expression levels, is likely to play an important role. Recently, Spielman et al. characterized variation in gene expression in cells from individuals belonging to three major population groups using the CEU, CHB and JPT samples from the HapMap Project. Their results indicate that the expression phenotype differs significantly between European-derived and Asian-derived populations for 1,097 of 4,197 genes tested. For the expression phenotypes with the strongest evidence of *cis* determinants, they found most of the variation is due to allele frequency differences at *cis*-linked regulators, suggesting that specific genetic variation among populations contributes appreciably to differences in gene expression phenotypes ([@b51-bbi-2008-015]). Akey et al. however, suggested that batch effects could be a confounding factor when interpreting their results ([@b2-bbi-2008-015]). By characterizing patterns of natural expression variation in 16 individuals from the CEU and YRI samples, Storey et al. found extensive variation in gene expression levels and estimated that approximately 83% of genes are differentially expressed among individuals and that approximately 17% of genes are differentially expressed between the two populations. Furthermore, by decomposing total gene expression variation into within- versus among-population components, they found that most expression variation is due to variation among individuals rather than among populations, which parallels observations of extant patterns of human genetic variation ([@b52-bbi-2008-015]). In addition to confirming that common variants account for a substantial fraction of the between-population gene expression variation, Zhang et al. were able to evaluate the contribution of genetic and non-genetic factors to the observed population differences using 176 CEU and YRI samples ([@b60-bbi-2008-015]). The above studies were performed to associate expression phenotype with one form of genetic variation, namely, SNPs. In contrast, Stranger et al. determined the overall contribution of SNPs and copy number variants (CNVs), which belong to another type of common genetic variation (i.e. structural variation) to expression phenotype by performing association analyses of expression levels of 14,925 transcripts with SNPs and CNVs in individuals of the four populations from HapMap Project. They found that SNPs and CNVs captured 83.6% and 17.7% of the total detected genetic variation in gene expression, respectively, but the signals from the two types of variation had little overlap, suggesting interrogation of the genome for both types of variants may be an effective way to elucidate the variation in complex phenotypes and human diseases ([@b54-bbi-2008-015]).

In addition to many differences between populations in transcriptional and translational regulation of genes, alternative pre-mRNA splicing (AS) is also likely to play an important role in regulating gene expression and generating variation in mRNA and protein isoforms. It has been estimated that between one-third and two-thirds of all human genes undergo AS ([@b50-bbi-2008-015]) and the disruption of specific AS events has been implicated in several human genetic diseases ([@b23-bbi-2008-015]). Using 22 unrelated CEU samples from the HapMap Project, Hull et al. demonstrated that six out of 70 exon-skipping events they identified were consistently different in splicing pattern between individuals, with a highly significant association between splice phenotype and neighboring SNPs. Their findings suggest that phenotypic variation in splicing patterns is determined by the presence of SNPs within flanking introns or exons ([@b31-bbi-2008-015]). Using a comprehensive exon-targeted microarray, Kwan et al. examined individual-specific alternative splicing in 60 unrelated CEU samples from the HapMap Project as well as 14 more CEPH samples. They showed that their approach can detect both annotated and novel alternatively spliced variants, and that such variation among individuals is heritable and genetically controlled ([@b40-bbi-2008-015]).

Application to Pharmacogenomics
===============================

It has been especially difficult to dissect genetic contribution to common, polygenic diseases as well as other clinical phenotypes such as drug response in which multiple genetic and environmental factors may interact with each other. It is now widely accepted that association studies offer greater statistical power over linkage in detecting genetic effects underlying these complex traits when the causative variant is common in the population ([@b48-bbi-2008-015]). Besides being used in traditional candidate gene approaches, the HapMap resource and technology for genome-wide analysis have enabled an unbiased approach to detect clinically important genetic factors that determine drug effectiveness and side effects between patients ([@b18-bbi-2008-015]; [@b5-bbi-2008-015]).

Clinical drug responses reflect not only properties intrinsic to the target cell but also host metabolic properties, drug-drug interactions, and pharmaco-kinetics as well as population, gender, age and other environmental factors. To evaluate population and gender effects and to begin to understand how genetic variations contribute to these effects, Huang et al. used CEU and YRI trios from the HapMap Project to study the population- and gender-specific differences for cytotoxicity following treatment with carboplatin, cisplatin, daunorubicin, and etoposide ([@b30-bbi-2008-015]). They observed large inter-individual variance in cytotoxicity as represented by IC~50~ (the drug concentration resulting in 50% cell growth inhibition) values for the four drugs for both the YRI and CEU samples. They also reported drug response differences between the two populations for two of the drugs they tested as well as a significant difference between females and males in the YRI samples for the two platinating agents. Differences in sensitivity to drugs may be explained, to some extent, by differences in gene expression between males and females ([@b59-bbi-2008-015]) or differences between populations ([@b60-bbi-2008-015]). Their results show that population and gender may affect risk for toxicities associated with certain chemotherapeutic agents.

One of the major goals of pharmacogenomic studies is to identify genetic factors responsible for drug effectiveness and side effects among patients. When the candidate gene is known, Jones et al. demonstrated that the HapMap resource is useful for pharmacogenetic discovery by using HapMap cell lines and HapMap SNPs to test whether a thiopurine methyltransferase (TPMT) polymorphism could be identified as predicting TPMT phenotype ([@b37-bbi-2008-015]). However, challenges remain for definitive gene identification when an unsupervised genome-wide approach is employed. Recently, Huang et al. used a comprehensive microarray platform to measure gene expression levels of the CEU and YRI trios from the HapMap Project and performed genome-wide association studies with \~380,000 highly informative HapMap SNPs to successfully identify genetic factors that contribute to the cytotoxicity of cisplatin and etoposide, which are widely prescribed anticancer agents ([@b28-bbi-2008-015]; [@b29-bbi-2008-015]). Utilizing the HapMap resource, these authors were able to use a genome-wide approach to evaluate associations between 1) genotype and drug response, 2) genotype and gene expression, and 3) gene expression and drug response. The HapMap resource has allowed these authors to find significant SNPs associated with both baseline gene expression and relative drug response. Therefore, genotype, gene expression and sensitivity to drug information can be used to identify genetic variants responsible for drug response that act through expression. Clearly, this level of integration of genotype, expression data and other phenotypic data could not be possible without a HapMap-like resource. In addition, these results will be useful to other investigators studying these lines, as the drug response data are also publicly available. Though further functional validation experiments are necessary to confirm the findings, Huang et al. showed that utilization of the HapMap resource impressively narrowed down the number of candidate genetic variants from hundred of thousands to just a handful that explain a significant percentage of the human variation in drug sensitivity. They hypothesize that each drug has a "pharmacogenetic signature" that explains most of the variation in drug sensitivity. These pharmacogenetic signatures can be integrated into clinical studies to determine whether they predict for patients at risk for chemotherapeutic-induced toxicities or response. The goal is to improve responsiveness and reduce adverse events associated with these highly toxic drugs.

Advantages and Limitations of the HapMap Resource
=================================================

There are several advantages of the HapMap resource. Investigators can utilize extensive genotype, gene expression and other phenotypic data on the 270 HapMap samples to perform various genome-wide scans for studies that do not require *a priori* knowledge, as well as more directed studies using a candidate gene approach. The HapMap samples provide an *in vitro* model for studies of the major world populations, i.e. European, African and Asian (including Chinese and Japanese). Another advantage to using these samples in pharmacogenomic studies of drug targets is that a cellular approach avoids the complexities of *in vivo* pharmacokinetic variability. Thus, genetic variation important in variation in pharmacodynamic effects can be teased out. Furthermore, such *in vitro* studies are less expensive and require less time than similar studies in human subjects, which would also need to consider the potential risks of the drugs being tested. Chemotherapy, for example, is associated with severe toxicity and therefore cannot be given to unaffected family members for genetic studies. A number of tools and techniques are now available to increase the ease of utilizing the HapMap resource, including tools for viewing and analyzing haplotype and LD data, identification of optimal sets of haplotype tagging SNPs, drawing links between associated SNPs and putative causal alleles or simply viewing LD and haplotypes across a gene or region of interest ([@b7-bbi-2008-015]).

However, there are some limitations of the HapMap resource. LCLs represent just one human tissue type, therefore it may not reflect tumor response or sensitivity of target tissue of known toxicity. It has been estimated that only \~50--60% of human genes are expressed in LCLs ([@b14-bbi-2008-015]). A more comprehensive understanding of variation of complex traits or phenotypes such as gene expression requires cell lines derived from other tissues, because for example it has already been known that many pharmacology-related genes have distinct tissue-specific expression patterns ([@b61-bbi-2008-015]). Because of the fact that the EBV-transformation of LCLs from the CEU and other HapMap samples (YRI, CHB, JPT) happened over 20 years apart ([@b17-bbi-2008-015]; [@b33-bbi-2008-015]), certain non-genetic factors, such as the EBV strains used for transformation or the number of freeze/thaw cycles, could lead to differences in gene expression between these samples, thus the comparative results using these samples could be confounded by non-genetic factors. An appropriate approach that takes consideration of these effects, therefore, is recommended for these studies ([@b2-bbi-2008-015]). Studies suggest EBV transformation may affect the expression of some genes and certain biological processes in LCLs ([@b41-bbi-2008-015]; [@b57-bbi-2008-015]). Therefore, interpretation of results using these cell lines may be biased by this effect.

Conclusion and Outlook
======================

The HapMap resource has allowed population-based studies regarding the contribution of genetic factors to variation in complex traits or phenotypes such as gene expression, drug response and susceptibility/cause of common disease in humans, as well as other studies in population genetics and evolution. For example, recent progess using the HapMap resource has begun to illustrate the contribution of common genetic variants to natural variation in gene expression within and among major world populations. Studies like these are providing new insights into the human genome and cell biology, thus changing our view of ourselves. The HapMap resource is also facilitating pharmacogenomic studies to identify genetic variants important in gene expression and sensitivity to chemotherapy, thus lending the promise of personalized medicine in the future.

Clearly, recent studies using the HapMap resource have shown its applicability to detect common genetic variants important for variation in complex traits or phenotypes such as development of common diseases ([@b1-bbi-2008-015]; [@b6-bbi-2008-015]; [@b38-bbi-2008-015]; [@b49-bbi-2008-015]) and the two areas of focus in this review: gene expression and drug response. However, the HapMap resource will become an even more powerful tool if it is integrated with other resources such as a full catalogue of functional variants, databases of genetic elements (e.g. transcript factor binding sites, exonic splicing enhancers and microsatellites) and databases of functional annotations (e.g. gene ontology and known pathways). Since the current HapMap genotypic data is comprised of \~4 million common SNPs, it remains a challenging task to identify rare or untyped SNPs using this resource. Therefore, deep resequencing or a denser genotyping microarray may be needed to uncover more SNPs in the HapMap samples. One effort to resequence the HapMap samples is the coordination of the HapMap Project and the ENCODE (ENCyclopedia Of DNA Elements) Project ([@b20-bbi-2008-015]). The latter aims to identify all functional elements in the human genome and involves resequencing of 10 500Kb HapMap-ENCODE regions in 48 unrelated individuals (16 YRI, 16 CEU, 8 CHB and 8 JPT) using a PCR-based method. Approximately 20,000 SNPs were identified in the HapMap-ENCODE regions. Some of these were already represented in dbSNP, while others were discovered during the resequencing. Genotype data were obtained from these SNPs of all 270 HapMap samples. The candidate gene approach, which requires *a priori* knowledge of certain biological processes or pathways, can be complemented by targeted deep resequencing to discover rarer variants, while the whole-genome approach using the HapMap resource can be used to identify new targets of interest in an unbiased way. Finally, as more and more genotypic and phenotypic data on the HapMap samples are made publicly available by researchers worldwide, sharing and cross-referencing these datasets will be difficult. Therefore, it is evident that appropriate bioinformatics techniques and statistical methods need to be developed so that researchers have the opportunity to comprehensively incorporate the complex networks of various relationships (e.g. gene-environment, gene-drug, gene-gender, gene-age, *cis*- or *trans*- regulators) that affect complex traits.

Some of the research described in this review was funded through our Pharmacogenetics of Anticancer Agents Research (PAAR) Group (<http://pharmacogenetics.org>) by the NIH/NIGMS grant U01GM61393. We are grateful to Dr. Shiwei Duan for creating the Figure.
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###### 

Publicly available genotypic, gene expression and pharmacology-related data on the HapMap cell lines.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Date type                                              GEO ID                                                Technology platform                             Samples                             No. Of targets   Web site                                     Reference
  -------------------------------- --------------------- ----------------------------------------------------- ----------------------------------------------- ----------------------------------- ---------------- -------------------------------------------- ------------------------------------------
  Genotype                         SNPs                                                                        Affymetrix 100K and 500K SNP Arrays; Perlegen   90 CEU, 90 YRI, 45 CHB and 45 JPT   \~4 million      <http://www.hapmap.org/>                     [@b56-bbi-2008-015]; [@b25-bbi-2008-015]

                                   SNPs                  GSE5013                                               Affymetrix 500K EA Array                        90 CEU, 90 YRI, 45 CHB and 45 JPT   \~474,000        <http://www.ncbi.nlm.nih.gov/geo/>\          [@b47-bbi-2008-015]
                                                                                                                                                                                                                    <http://www.hapmap.org/>                     

                                   CNV loci                                                                    Spectral Genomics 1 Mb Human BAC Array          55 CEU                              \~2,600          <http://projects.tcag.ca/variation/>         [@b32-bbi-2008-015]

                                   CNV loci                                                                    Whole Genome TilePath Array                     90 CEU, 90 YRI, 45 CHB and 45 JPT   \~27,000         <http://www.sanger.ac.uk/humgen/cnv/data/>   [@b54-bbi-2008-015]

  Expression                       Transcripts           GSE5859                                               Affymetrix Human Focus Array                    60 CEU, 41 CHB and 41 JPT           \~8,500          <http://www.ncbi.nlm.nih.gov/geo/>           [@b51-bbi-2008-015]

                                   Transcripts           GSE7792\                                              Affymetrix Human Exon Array                     87 CEU and89 YRI                    \~18,000         <http://www.ncbi.nlm.nih.gov/geo/>           [@b28-bbi-2008-015]; [@b60-bbi-2008-015]
                                                         GSE7851[†](#tfn1-bbi-2008-015){ref-type="table-fn"}                                                                                                                                                     

                                   Transcripts           GSE7236                                               Affymetrix Human Focus Array                    8 CEU and8 YRI                      \~8,500          <http://www.ncbi.nlm.nih.gov/geo/>           [@b52-bbi-2008-015]

                                   Transcripts           GSE6536                                               Illumina Sentrix Human-6 Expression BeadChip    60 CEU, 60 YRI, 45 CHB and 45 JPT   \~47,000         <http://www.ncbi.nlm.nih.gov/geo/>           [@b54-bbi-2008-015]; [@b55-bbi-2008-015]

  Pharmacology-related Phenotype   Drug response, etc.                                                                                                         Various                                              <http://www.pharmgkb.org/>                   [@b39-bbi-2008-015]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A version filtered out probesets affected by SNPs.
